Quick Answer
Context Therapeutics Inc. reported Diluted EPS of $0.38 per share (loss) for fiscal year 2025.
Context Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.38 | +17.4% |
| 2024 | -$0.46 | +69.3% |
| 2023 | -$1.50 | -61.3% |
| 2022 | -$0.93 | +74.8% |
| 2021 | -$3.69 | +6.8% |
| 2020 | -$3.96 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.10 | +54.5% | -11.1% |
| June 30, 2025 | -$0.09 | -125.0% | -80.0% |
| March 31, 2025 | -$0.05 | +78.3% | +77.3% |
| September 30, 2024 | -$0.22 | +40.5% | -450.0% |
| June 30, 2024 | -$0.04 | +87.1% | +82.6% |
| March 31, 2024 | -$0.23 | +42.5% | +37.8% |
| September 30, 2023 | -$0.37 | -54.2% | -19.4% |
| June 30, 2023 | -$0.31 | -24.0% | +22.5% |
- Context Therapeutics Inc. showed an increase of +17.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Context Therapeutics Inc.’s diluted eps has grown by 90.4% (from $3.96 per share (loss) to $0.38 per share (loss)).
- The most recent figure is from Context Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: